Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Marathon Pharma to Pause Muscular Dystrophy Drug Launch After Criticism of 6,000% Price Hike

By Ryan Bushey | February 14, 2017

Diego G Diaz / Shutterstock, Inc.

Another drug company reignited the debate over appropriate pricing policies for important medications.

Northbrook, Illinois-based Marathon Pharmaceuticals gained approval from the Food and Drug Administration (FDA) on Thursday for a Duchenne muscular dystrophy (DMD) treatment called Emflaza.

The drug is a decades-old corticosteroid generically named deflazacort. It’s now the first steroid to gain regulatory approval to treat the debilitating genetic disorder, according to Reuters.

However, Marathon has come under criticism for making the list price of this treatment $89,000 a year even though the firm promised an assistance program that could push the price down to $54,000 through rebates and discounts.

Previously, patients in the U.S. were able to import deflazacort from the Canada and the United Kingdom where it was available for an estimated $1,000 a year, but the availability of an FDA-approved product like this means patients won’t have this option anymore.

This decision caught the attention of two democratic lawmakers. Senators Bernie Sanders and Elijah Cummings sent a letter to the company’s CEO calling the pricing decision, “outrageous”, while asking Marathon to provide supplementary information regarding research and development costs and how it decided to set that price, explained Bloomberg.

Furthermore, the legislator’s letter accused Marathon of abusing the FDA’s orphan drug program, which grants companies several years of marketing exclusivity in order to foster research and development efforts focusing on rare disease treatments. The senators noted the program is not intended to provide companies like Marathon with “lucrative market exclusivity rights” for drugs that were not invented by Marathon and have been available for decades.

Sanders and Cummings ended their letter asking Marathon to submit the requested information by February 27th while encouraging the company to lower the price before it arrives on the market next month.

On Monday night, Marathon’s CEO Jeffrey Aronin released a statement acknowledging the concerns writing commercialization efforts for Emflaza would be paused for an unspecified time period. Aronin promised to meet with Duchenne community leaders to explain their commercialization plans, discuss concerns, analyze options going forward, and formulate a new launch plan going forward. 

Also, the CEO promised to maintain the expanded access program for patients currently receiving the drug while adding that the export option was still available. 

This news comes after PhRMA, the drug industry’s largest trade-group, launched a marketing campaign to bolster public perception of these companies after a number of controversies emerged over drug pricing like with Martin Shkreli and furor over the EpiPen cost increases.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE